Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies

US11071788B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Anne-Sophie REBSTOCK · Écully, FR
• Yolanda Cancho Grande · Leverkusen, DE
• Sven Wittrock · Berlin, DE
• Sandra BERNDT · Hohen Neuendorf, DE
• Uwe Gritzan · Cologne, DE
• Jenny Fitting · Aachen, DE
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Patrick L. Jones · Danvers, US
• Christoph MAHLERT · Wuppertal, DE
• Christian Votsmeier · Cologne, DE
• Dorian Schönfeld · Cologne, DE
• Mark Trautwein · Whippany, US
• Ernst Weber · Langenfeld, DE
• Nikolaus Pawlowski · Cologne, DE
• Simone Greven · Dormagen, DE
• Julian Marius Glück · Meerbusch, DE
• Stefanie HAMMER · Berlin, DE
• Lisa DIETZ · Wuppertal, DE
• Stephan MÄRSCH · Cologne, DE

Key dates

• Filing date: Jun 20, 2016
• Grant date: Jul 27, 2021
• Expiry date: Mar 8, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.